SMX 18-001
NCT03781063
JCP087
An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation
Status:
Recruiting
II
Phase
2nd+
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
ER+, HER2-, ESR1
Investigational
Product
Lasofoxifene
Selective modulator of the estrogen receptor (SERM) (p.o.)
Treatment Arms
o Experimental: Lasofoxifene
o Active Comparator: Fulvestrant